While 1 nM of R1881 (an androgen mimetic) overcomes the effect of enzalutamide due to decreased drug target engagement, ARCC-4 still induces degradation of the androgen receptor to block prostate cancer cell growth even in the presence of 10 nM R1881. Here, AR is linked to prostate cancer.